---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-291979"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-11-24T23:59:59+00:00"
generated_at: "2026-05-16T17:29:03.873814+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered

## Summary
- First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.
- Payment expected within 30 days; net proceeds after ~24.1% to Israel Innovation Authority and ~21.5% to Hadasit.
- OpRegen is being evaluated in Phase 2a GAlette trial for geographic atrophy secondary to AMD.
- Milestone based on manufacturing and clinical advancements in the OpRegen cell therapy program.

## SEC filing metadata
- accession: 0001193125-25-291979
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-11-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/0001193125-25-291979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000119312525291979/lctx-20251120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-291979
- JSON: https://secwatch.observer/filing/0001193125-25-291979.json
- Plain text: https://secwatch.observer/filing/0001193125-25-291979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.